Compare Flex Ltd (FLEX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flex Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Flex Ltd trades at $99.25 (market cap $40.97B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Flex Ltd is far larger — about 42.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Flex Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flex Ltd for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FLEX | MRVI | |
|---|---|---|
Market Cap | $40.97B | $972.90M |
Volume | 5,533,554 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $162.07 | $9.00 |
52-Week Low | $54.51 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $44.06B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLEX trades at $110.88, down 5.42% over the past day, amid a broader market pullback. The stock maintains a bullish technical trend with strong analyst support, including a consensus price target of $147.50. Recent acquisitions like EPC Power and the planned spin-off of Axiom highlight strategic moves to capitalize on AI data center and power infrastructure growth. Fundamentals show solid profitability with a net income margin of 3.32% and revenue growth to $29.3B projected for 2026.
The outlook for FLEX is positive, driven by expansion in AI infrastructure and consistent earnings beats. Investment opportunities include potential upside from the Axiom spin-off and continued demand in cloud and power sectors. Key risks involve integration challenges from acquisitions, competitive pressures, and market volatility affecting valuation multiples.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flex Ltd
Flex provides design, engineering, manufacturing, supply chain, and logistics services for technology products. It serves industries including cloud, data centers, communications, automotive, healthcare, and industrials.
Read more on FLEX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
